Xia Ting, He Wen, Luo Zhenye, Wang Kexin, Tan Xiaomei
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, PR China; Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Southern Medical University, Guangzhou 510515, PR China; Guangdong Provincial Engineering Laboratory of Chinese Medicine Preparation Technology, Guangzhou 510515, PR China.
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, PR China; Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Southern Medical University, Guangzhou 510515, PR China; Guangdong Provincial Engineering Laboratory of Chinese Medicine Preparation Technology, Guangzhou 510515, PR China.
Int J Biol Macromol. 2024 Jun;270(Pt 2):132256. doi: 10.1016/j.ijbiomac.2024.132256. Epub 2024 May 9.
Gut microbiota variances reflecting the severity type 2 diabetes mellitus (T2DM). Achyranthes bidentata polysaccharide (ABP) can regulate gut microbiota. However, the hypoglycemic effect and underlying mechanism of ABP remain unclear. Herein, we characterized the structure of ABP and revealed the hypoglycemic effect of ABP in mice with T2DM. ABP repaired the intestinal barrier in T2DM mice and regulated the composition and abundance of gut microbiota, especially increasing bacteria which producing short-chain fatty acids (SCFAs), then increasing glucagon-like peptide-1 (GLP-1) level. The abundance of these bacteria was positively correlated with blood lipid and INS levels, negatively correlated with FBG levels. Colon transcriptome data and immunohistochemistry demonstrated that the alleviating T2DM effect of ABP was related to activation of the GLP-1/GLP-1 receptor (GLP-1R)/cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)/cAMP-response element binding protein (CREB)/INS pathway. Fecal microbiota transplantation (FMT) confirmed the transmissible efficacy of ABP through gut microbiota. Overall, our research shows that ABP plays a hypoglycemic role by increasing gut microbiota-derived SCFAs levels, and activating the GLP-1/GLP-1R/cAMP/PKA/CREB/INS pathway, emphasizing ABP as promising T2DM therapeutic candidates.
肠道微生物群的变化反映了2型糖尿病(T2DM)的严重程度。牛膝多糖(ABP)可以调节肠道微生物群。然而,ABP的降血糖作用及其潜在机制仍不清楚。在此,我们对ABP的结构进行了表征,并揭示了ABP对T2DM小鼠的降血糖作用。ABP修复了T2DM小鼠的肠道屏障,调节了肠道微生物群的组成和丰度,特别是增加了产生短链脂肪酸(SCFAs)的细菌,进而提高了胰高血糖素样肽-1(GLP-1)水平。这些细菌的丰度与血脂和胰岛素水平呈正相关,与空腹血糖水平呈负相关。结肠转录组数据和免疫组织化学表明,ABP缓解T2DM的作用与GLP-1/GLP-1受体(GLP-1R)/环磷酸腺苷(cAMP)/蛋白激酶A(PKA)/cAMP反应元件结合蛋白(CREB)/胰岛素(INS)通路的激活有关。粪便微生物群移植(FMT)证实了ABP通过肠道微生物群的可传递功效。总体而言,我们的研究表明,ABP通过提高肠道微生物群衍生的SCFAs水平和激活GLP-1/GLP-1R/cAMP/PKA/CREB/INS通路发挥降血糖作用,强调ABP作为有前景的T2DM治疗候选药物。